VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Topalian on Biomarkers for Anti- PD-1 Therapies in Melanoma

Suzanne L. Topalian, MD
Published: Thursday, Feb 12, 2015


Suzanne Topalian, MD, professor of surgery and oncology, John Hopkins Medicine, and director of the melanoma program, Sidney Kimmel Comprehensive Cancer Center,  compares biomarker detection for anti- PD-1 therapies like nivolumab to anti-CTLA-4 therapies like ipilimumab for the treatment of melanoma.

PD-1 and PD-L1 blocking drugs are more active at the tumor site, says Topalian. To determine markers for PD-1 drugs , investigators must look at the tumor itself and correlate them with clinical outcomes.  Anti-CTLA-4 therapies have a global impact on the immune response, so markers such as PD-L1 may not be relevant.  


Suzanne Topalian, MD, professor of surgery and oncology, John Hopkins Medicine, and director of the melanoma program, Sidney Kimmel Comprehensive Cancer Center,  compares biomarker detection for anti- PD-1 therapies like nivolumab to anti-CTLA-4 therapies like ipilimumab for the treatment of melanoma.

PD-1 and PD-L1 blocking drugs are more active at the tumor site, says Topalian. To determine markers for PD-1 drugs , investigators must look at the tumor itself and correlate them with clinical outcomes.  Anti-CTLA-4 therapies have a global impact on the immune response, so markers such as PD-L1 may not be relevant.  




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x